About this resource:
Source: The Cochrane Collaborative
Last Reviewed: June 2017
Workgroups: Arthritis Workgroup
This Cochrane systematic review assesses the benefits and harms of celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), in people with rheumatoid arthritis. This systematic review included 8 randomized control trials with durations of 4 to 24 weeks, published between 1998 and 2014, that involved a total of 3,988 adults (mean age = 54 years), most of whom were women (73%), and found that celecoxib may improve clinical symptoms, alleviate pain, and contribute to little or no difference in physical function compared with placebo.
Fidahic, M., Jelicic Kadic, A., Radic, M. & Puljak, L. Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews, 2017 (6). DOI: 10.1002/14651858.CD012095.pub2.